# APPENDIX 1

# **Appendix Table 1.** List of interview questions to collect information on how a report is processed by different groups of users.

Theme	Questions					
Content/layout	How do you receive your reports and what format are they in?					
	In what order are you looking for information in the report?					
	What do you want to know first?					
	Where to find it?					
	Are there specific concepts or points you are looking for when scanning through the report?					
	What is the essential information?					
	What is hard to understand/easy to understand?					
	How do you know which analyses are done and not done, and why is it important?					
	How often do reports inform treatment directly?					
	How do you know what the next step in the process is?					
	Do you know what is expected of you?					
	What do you like/dislike about reports?					
Communication	With the patient:					
	• How and what do you communicate to your patients to communicate the results?					
	<ul> <li>Do you refer patients for genetic counselling?</li> </ul>					
	With the producer:					
	<ul> <li>How often do you have to go back to NGS lab for clarification?</li> </ul>					
The dream	What challenges and needs are there from your perspective?					
	If the clinical report was not a paper report/PDF, what would it be instead?					

# Appendix Table 2. List of interview questions for evaluation of developed prototypes.

Theme	Questions
Content/layout	It is easy to find result of the test in the report (Scale)
	The information in the report is complete (Scale)
	The results/findings presented in the report are easy to understand (Scale)
	The report is well-structured (Scale)
	The conclusion of the test is clear (Scale)
	After reading the report I know what my next step is (Scale)
VUS	It is clear what implications VUS has on the patient's diagnosis (Scale)
Secondary findings	It is clear that secondary findings were intentionally searched for (Scale)
	Please indicate if secondary findings were included in the report (Yes/No)
Data reanalysis	Does the report contain information about the possibility of future data reanalysis? (Yes/No)
Communication	It is easy to use the report to communicate findings to a patient (Scale)
General open-	Which set of reports do you prefer? Why? (open-ended)
ended questions	What did you like best in the report template? (open-ended)
	What did you like least in the report template? (open-ended)
	Do you have any suggestions to improve the template? (open-ended)

# APPENDIX 2

A set of redesigned prototype reports for three fictional clinical cases: report A contains a likely pathogenic finding; report B contains a VUS and a secondary pathogenic finding in the BRCA2 gene; report C contains no findings of clinical significance.

Patient

Name:

Gender:

Date of birth:

Dr. Jan Johansen Smith University Hospital Garry Building, Western Rd, Brighton BN3 5BW, UK

Brighton, 28.05.2019

#### **Questions about this report?**

See our website: www.smithgenetics.com/reports Call our genetic specialists: +44 371-227000

# Sample information

**Analysis performed** 

Sample ID:	Case1_MN
Sample type:	Blood
Received:	20.05.2019

# 22.08.2018 **Clinical indication and reported phenotypes**

Male

NORDAHL, Mattias

Diagnosis arthrogryposis multiplex congenita (AMC). Contractures in fingers, feet and knees. Big skull with prominent forehead with hemangioma that spreads over thoracic spine and sacral pit. Short nose, long filtrum, downward mungipor, long eyelashes.

# Result 1 2 3 5 Likely pathogenic

Pathogenic findings

A likely pathogenic variant in MYH3 was found.

# Conclusion

Genomic variants are classified on a five-point scale to indicate the likelihood that the variant is associated with disease. In this case, a likely pathogenic variant in MYH3 was identified. We interpret this as the likely cause of the patient's phenotype and as genetic evidence of the diagnosis Arthrogryposis Multiplex Congenita (AMC)<sup>1</sup>.

Exome sequencing of proband, mother and father (Agilent

SureSelect Human All Exon 60 Mb), and trio analysis of

coding exons along with flanking +/-20 intronic bases.

We highly recommend that the family is referred for genetic counseling as follow-up. See further details and recommendations below.

Main findings			
Gene	Variant	Zygosity	Classification
МҮН3	(NM_002470.3)c.700G>A (p.Ala234Thr)	Homozygous	4 - Likely pathogenic

Nomenclature according to HGVS (v2.121101) (www.hgvs.org/mutnomen)

#### Interpretation

A biallelic variant in MYH3 was identified in the patient. MYH3 encodes the embryonic isoform of myosin heavy-chain (MyHC) that is expressed during fetal life. Myosin is a molecular motor and the essential part of the thick filament of striated muscle.

Pathogenic variants in MYH3 are reported to cause autosomal dominant distal arthrogryposis type 2A, 2B and 8 and autosomal recessive spondylocarpotarsal synostosis syndrome.

The patient is homozygous for c.700G>A (p.Ala234Thr) in MYH3, inherited from heterozygous parents. The variant is not present in a database of presumed healthy individuals<sup>2</sup> and it is reported heterozygote in two individuals with distal arthrogryposis. We regard this variant as being likely pathogenic and thus interpret this to be the likely cause of the patient's phenotype, and as genetic evidence of the diagnosis Arthrogryposis Multiplex Congenita (AMC).

We recommend that the family is referred for genetic counseling for follow-up.

#### **Recommended follow-up**

#### 1. Refer family for genetic counseling

Inform of the consequences of the findings in this report and discuss options for further testing.

#### 2. Annual screening for liver disease

Pathogenic variants in MYH can be associated with an increase risk of liver disease, annual screening is recommended.

#### References

- 1. OMIM #618484
- 2. Database: gnomAD, Broadinstitute

# **Further information**

Foreningen for Muskelsyke: **ffm.no** Senter for sjeldne diagnoser: **sjeldnediagnoser.no** Search **ClinicalTrials.gov** and **ClinicalTrialsRegister.eu** for clinical studies on AMC and related conditions.

#### Information for patients

Please contact the physician who ordered this test for help interpreting the results: **Dr. Jan Johansen** 

See our website **www.smithgenetics.com/patient** for general information and a list of genetic specialists and counselors in your area.

# Appendix



#### Disclaimer

Exome sequencing covers approximately 95 % of the genomic variation located on protein coding regions. The analysis is mainly targeted to the coding regions and intronic splice site regions of genes in the insilico gene panel (see list of included genes below). Exome sequencing does not cover all intronic regions or all non-cod-ing regions, such as UTR's (untranslated regions) of genes. Some genomic regions, such as regions with repetitive elements or genes with nearly identical copies/pseudogenes, can not reliably be analyzed by exome sequencing.

#### Methods used

Blood samples from the family trio were collected in EDTA tubes 20.05.2019 and received for sequencing on the same day. Genomic DNA was extracted with Agilent gDNA Extraction Kit following the manufacturer's protocol. The exome library was captured with the Agilent SureSelect Human All Exon V6 kit following the manufacturer's protocol. The generated library was sequenced on an Illumina NextSeq 500 System to an average coverage depth of ≥ 80x.

An end-to-end in-house bioinformatics pipeline was applied including conversion of base calls to fastq files (bcl2fastq2 Conversion Software v2.20), alignment of reads (bwa v. 0.7.17) to GRCh37/hg19 genome assembly, pre-processing of alignment files (GATK v.3.8.1), variant calling (GATK Haplotype caller v.3.8.1), variant filtering and annotation with Illumina Variant Studio 2.2. The bioinformatics pipeline called SNPs and INDELs shorter than 50 bp.

Evaluation was limited to the HCM LQT insilico gene panel (see details below), and ACMG recommended genes for reporting of secondary findings, www.ncbi.nlm.nih.gov/clinvar/docs/acmg/ (Kalia et al., 2017) with a focus on coding exons along with flanking +/-20 intronic bases. Variants were categorized into 5 classes according to the ACMG guidelines (Richards et al., 2015). Only rare variants with allele frequency lower than 0.01 currently associated with patient phenotype were verified by Sanger sequencing and reported. Variants classified as pathogenic, likely pathogenic and variants of uncertain significance are included in the report.



#### Included genes

75 genes are included in the insilico HCM LQT gene panel. For detailed information on the gene panel visit **www.smithgenetics.com/panels/HCM\_LQT/**. In total the gene panel HCM LQT covers a maximum of 100% of the combined coding regions ± 2bp intronic sequence of the following genes:

Α	В	F	G	L	R	V
ABCA1	BLOC1S3	F10	GATA1	LYST	RASGRP2	VIPAS39
ABCC4	BLOC1S6	F11	GFI1B	Μ	RUNX1	VPS33B
ABCG5 ABCG8 ACTN1	<b>C</b> COL1A1	F13A1 F13B	GP1BA GP1BB	MPIG6B MPL	<b>S</b> SERPINE1	<b>W</b> WAS
ACTN1 ACVRL1	COL3A1	F2 F2R	GP6 GP9	MYH3	SERPINF2	
ADAMTS13 ADRA2A ANKRD18A ANKRD26 ANO6 AP3B1 AP3D1 ARPC1B ANKRD26 ANO6 AP3B1	COL5A1 COL5A2 CYCS D DIAPH1 DTNBP1 E ENG EPHB2 ETV6	F2RL3 F5 F7 F8 F9 FERMT3 FGA FGB FGG FLI1 FLNA	H HOXA11 HPS1 HPS3 HPS4 HPS5 HPS6 I ITGA2 ITGA2B ITGA3	N NBEA NBEAL2 O ORAI1 P P2RY1 P2RY12 P4HB PLA2G4A PLAU	SLFN14 SMAD4 SRC STIM1 STX11 STXBP2 <b>T</b> TBXA2R TBXA2R TBXAS1 THBD THPO TPM4	
AP3D1 ARPC1B		FYB		PRKACG PTGS1	TUBB1	

Brighton, 28.05.2019

#### Questions about this report?

See our website: www.smithgenetics.com/reports Call our genetic specialists: +44 371-227000

# Sample information

Sample ID:	Case2_AH
Sample type:	Blood
Received:	24.04.2018

# Analysis performed

Exome sequencing of proband, mother and father (Agilent SureSelect Human All Exon 60 Mb), and trio analysis of coding exons along with flanking +/-20 intronic bases.

#### Conclusion

Genomic variants are classified on a five-point scale to indicate the likelihood that the variant is associated with disease. In this case, no certain molecular cause of AMC<sup>1</sup> was identified. However, biallelic variants of uncertain significance were identified in RARS. The family should be referred for genetic counseling. See further details and recommendations below.

# Main findings

Gene	Variant	Zygosity	Classification
RARS	(NM_02887.3)c.668G>A (p.Arg223His)	Heterozygous, from father	3 - Uncertain significance
RARS	(NM_002887.3)c.1568T>A (p.Met523Lys)	Heterozygous, from mother	3 - Uncertain significance

Nomenclature according to HGVS (v2.121101) (www.hgvs.org/mutnomen)

#### Interpretation

RARS encodes a cytoplasmic tRNA synthetase for arginine, essential for translation from RNA to proteins. Pathogenic variants in RARS cause autosomal recessive hypomyelinating leukodystrophy type 9.

The patient is compound heterozygous for the variants c.668G>A (p.Arg223His) and c.1568T>A (p.Met523Lys) in RARS. The variants are inherited from her father and mother respectively. The variants p.Arg223His and p.Met523Lys are present in 8 and 0 individuals in a database of presumed healthy individuals<sup>2</sup> respectively, but have not previously been reported in patients with AMC. Our knowledge about these variants is not sufficient to conclude whether they are the cause of AMC or not. The family should be referred for genetic counseling for more information.

# Patient Name: HOVIK, Anna

Name: HOVIK, Anna Gender: Female Date of birth: 28.05.2013

#### Clinical indication and reported phenotypes

Arthrogryposis multiplex congenita (AMC), muscle hypotonia, global developmental delay. Brain MRI shows suspected dysgenesis and delayed myelination, microcephaly -3SD. Parents are healthy.

Result				
1	2	3 A Uncertain	4	5
Uncert	ain findings			

No certain cause of the phenotype was found.

#### About Variants of Unknown SIgnificance (VUS)

Read more about how VUS are classified, interpreted and reported: www.smithgenetics.com/vus

Secondar	y findings		
Gene	Variant	Zygosity	Classification
BRCA2	(NM_000059.3)c.8648delC (p.Pro2883Hisfs)	Heterozygous, from mother	5 - Pathogenic

#### Interpretation

In agreement with patient consent, we report that a heterozygous pathogenic variant in BRCA2 (c.8648delC, p.Pro2883Hisfs) was identified in the patient. This variant confers an increased risk of malignant breast- and ovarian tumors. The variant is inherited from the patient's mother. We highly recommend that Anna Høvik's mother is offered genetic counseling.

#### **Recommended follow-up**

- **1. Refer family for genetic counceling** to inform about the limitations of the performed test, the significance of the results and options for further testing.
- 2. Offer patient's mother genetic counceling regarding the secondary findings in BRCA2.
- 3. Re-analysis in 1 year

Re-analysis may provide more specific findings in the future and is recommended for this patient in 1 year.

#### References

- 1. OMIM #160720
- 2. Database: gnomAD, Broadinstitute

#### **Further information**

Senter for sjeldne diagnoser: **sjeldnediagnoser.no** Search **ClinicalTrials.gov** and **ClinicalTrialsRegister.eu** for clinical studies for AMC and related conditions.

#### Information for patients

Please contact the physician who ordered this test for help interpretating the results: **Dr. Jan Johansen** 

See our website **www.smithgenetics.com/patient** for general information and a list of genetic specialists and councelors in your area.

# Appendix



#### Disclaimer

Exome sequencing covers approximately 95 % of the genomic variation located on protein coding regions. The analysis is mainly targeted to the coding regions and intronic splice site regions of genes in the insilico gene panel (see list of included genes below). Exome sequencing does not cover all intronic regions or all non-cod-ing regions, such as UTR's (untranslated regions) of genes. Some genomic regions, such as regions with repetitive elements or genes with nearly identical copies/pseudogenes, can not reliably be analyzed by exome sequencing.

#### -→-→→ Methods used

Blood samples from the family trio were collected in EDTA tubes 18.04.2018 and received for sequencing on the same day. Genomic DNA was extracted with the Agilent gDNA Extraction Kit following the manufacturer's protocol. The exome library was captured with the Agilent SureSelect Human All Exon V6 kit following the manufacturer's protocol. The generated library was sequenced on an Illumina NextSeq 500 System to an average coverage depth of ≥ 80x.

An end-to-end in-house bioinformatics pipeline was applied including conversion of base calls to fastq files (bcl2fastq2 Conversion Software v2.20), alignment of reads (bwa v. 0.7.17) to GRCh37/hg19 genome assembly, pre-processing of alignment files (GATK v.3.8.1), variant calling (GATK Haplotype caller v.3.8.1), variant filtering and annotation with Illumina Variant Studio 2.2. The bioinformatics pipeline called SNPs and INDELs shorter than 50 bp.

Evaluation was limited to the Arthrogryposes insilico gene panel (see details below), and ACMG recommended genes for reporting of secondary findings, www.ncbi.nlm.nih.gov/clinvar/docs/acmg/ (Kalia et al., 2017) with a focus on coding exons along with flanking +/-20 intronic bases. Variants were categorized into 5 classes according to the ACMG guidelines (Richards et al., 2015). Only rare variants with allele frequency lower than 0.01 currently associated with patient phenotype were verified by Sanger sequencing and reported. Variants classified as pathogenic, likely pathogenic and variants of uncertain significance are included in the report.



#### Included genes

75 genes are included in the insilico Arthrogryposes gene panel. For detailed information on the gene panel visit **www.smithgenetics.com/panels/arthrogryposes/**. In total the gene panel covers a maximum of 100% of the combined coding regions ± 2bp intronic sequence of the following genes:

Α	В	F	G	L	R	V
ABCA1	BLOC1S3	F10	GATA1	LYST	RASGRP2	VIPAS39
ABCC4	BLOC1S6	F11	GFI1B	м	RARS	VPS33B
ABCC4 ABCG5 ABCG8 ACTN1 ACVRL1 ADAMTS13 ADRA2A ANKRD18A ANKRD26 ANO6 AP3B1 ARPC1B ANKRD26 ANO6 AP3B1 ARPC1B	BLOC1S6 C COL1A1 COL3A1 COL5A2 CYCS D DIAPH1 DTNBP1 E ENG EPHB2 ETV6	F11 F13A1 F13B F2 F2R F2RL3 F5 F7 F8 F9 FERMT3 FGA FGB FGG FLI1 FLNA FYB	GFI1B GP1BA GP1BB GP6 GP9 <b>H</b> HOXA11 HPS1 HPS3 HPS4 HPS5 HPS6 <b>I</b> ITGA2 ITGA2B ITGA3	M MPIG6B MPL MYH9 N NBEA NBEAL2 O ORAI1 P P2RY12 P2RY12 P4HB PLA2G4A PLAU PLAU PRKACG PTGS1	RARS  SERPINE1 SERPINF2 SLFN14 SMAD4 SRC STIM1 STX11 STX11 STXBP2  T TBXA2R TBXA2R TBXAS1 THBD THPO TPM4 TUBB1	VPS33B W WAS

Brighton, 28.05.2019

#### Questions about this report?

See our website: http://www.smithgenetics.com/reports Call our genetic specialists: +44 371-227000

# Patient

Name:	CARLSON, Ivar
Gender:	Male
Date of birth:	28.01.1989

**Clinical indication and reported phenotypes** Dyskinetic cerebral palsy.

Epilepsy, scoliosis, speech disorder.

#### Result

No certain cause of the phenotype was found.

# Sample information

Sample ID:	Case3_IC
Sample type:	Blood
Received:	21.05.2019

#### Analysis performed

Exome sequencing of proband, mother and father (Agilent SureSelect Human All Exon 60 Mb), and trio analysis of coding exons along with flanking +/-20 intronic bases.

# Conclusion

No pathogenic variants are reported, and no certain molecular cause of dyskinetic cerebral palsy was identified in the patient.

#### Recommended follow-up

**1. Refer family for genetic counceling** to inform about the limitations of the performed test, the significance of the results and options for further testing.

#### 2. Re-analysis in 1 year

Re-analysis may provide more specific findings in the future and is recommended for this patient in 1 year.

#### Information for patients

Please contact the physician who ordered this test for help interpretating the results: **Dr. Jan Johansen** 

See our website **www.smithgenetics.com/patient** for general information and a list of genetic specialists and councelors in your area.

# Appendix



### Disclaimer

Exome sequencing covers approximately 95 % of the genomic variation located on protein coding regions. The analysis is mainly targeted to the coding regions and intronic splice site regions of genes in the insilico gene panel (see list of included genes below). Exome sequencing does not cover all intronic regions or all non-cod-ing regions, such as UTR's (untranslated regions) of genes. Some genomic regions, such as regions with repetitive elements or genes with nearly identical copies/pseudogenes, can not reliably be analyzed by exome sequencing.

#### →→→ Methods used

Blood samples from the family trio were collected in EDTA tubes 21.05.2019 and received for sequencing on the same day. Genomic DNA was extracted with the Agilent gDNA Extraction Kit following the manufacturer's protocol. The exome library was captured with Agilent SureSelect Human All Exon V6 kit following the manufacturer's protocol. The generated library was sequenced on an Illumina NextSeq 500 System to an average coverage depth of ≥ 80x.

An end-to-end in-house bioinformatics pipeline was applied including conversion of base calls to fastq files (bcl2fastq2 Conversion Software v2.20), alignment of reads (bwa v. 0.7.17) to GRCh37/hg19 genome assembly, pre-processing of alignment files (GATK v.3.8.1), variant calling (GATK Haplotype caller v.3.8.1), variant filtering and annotation with Illumina Variant Studio 2.2. The bioinformatics pipeline called SNPs and INDELs shorter than 50 bp.

Evaluation was limited to the Epilepsy insilico gene panel (see details below), and ACMG recommended genes for reporting of secondary findings, www.ncbi.nlm.nih.gov/clinvar/docs/acmg/ (Kalia et al., 2017) with a focus on coding exons along with flanking +/-20 intronic bases. Variants were categorized into 5 classes according to the ACMG guidelines (Richards et al., 2015). Only rare variants with allele frequency lower than 0.01 currently associated with patient phenotype were verified by Sanger sequencing and reported. Variants classified as pathogenic, likely pathogenic and variants of uncertain significance are included in the report.



#### Included genes

281 genes are included in the insilico Epilepsy gene panel. For detailed information on the gene panel visit **www.smithgenetics.com/panels/epilepsy/**. In total the gene panel covers a maximum of 100% of the combined coding regions ± 2bp intronic sequence of the following genes:

Α	В	F	G	L	R	V
ABCA1	BLOC1S3	F10	GATA1	LYST	RASGRP2	VIPAS39
ABCC4	BLOC1S6	F11	GFI1B	м	RUNX1	VPS33B
			GFI1B GP1BA GP1BB GP6 GP9 <b>H</b> HOXA11 HPS1 HPS3 HPS4 HPS5 HPS6 <b>I</b> ITGA2 ITGA2B	M MPIG6B MPL MYH9 N NBEA NBEAL2 O ORAI1 P P2RY1 P2RY12 P4HB PLA2G4A		
AP3D1 AP3D1 ARPC1B		FYB	ITGB3	PLAU PRKACG PTGS1	TPM4 TUBB1	